The Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) tablets and capsules in combination with Venclexta (venetoclax) for adults with chronic lymphocytic leukemia (CLL) or ...
FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...
The FDA has approved AstraZeneca’s Calquence (acalabrutinib) for adults with chronic lymphocytic leukemia and small ...
UK pharma major AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax has been approved in the USA as the ...
AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...
AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...
AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for ...
First and only all-oral, fixed-duration regimen designed to provide CLL patients with the potential to experience time off treatment –– Approval expands Genentech’s fixed-duration portfolio by ...
BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from ...
In recent years, Prime Video has been putting more Asian content into the spotlight, and the momentum is set to follow ...
PRIME Video previewed 2026 titles from Japan, Korea and India during “Prime Video Presents: International Originals,” its first global showcase dedicated to int ...
UOB Malaysia has extended a RM600 million (US$150 million) sustainability-linked loan (SLL) to RHB Banking Group.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results